Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
Norlin, Jenny M. ; Steen Carlsson, Katarina LU
; Persson, Ulf
LU
and Schmitt-Egenolf, Marcus
(2015)
In Acta Dermato-Venereologica
95(2).
p.156-161
- Abstract
- The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. This study was performed to estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including costs of long-term sick leave and disability pension, was estimated as the difference between psoriasis patients and matched controls from the general population. Total direct cost increased from SEK 348 million (similar to(sic)39) in 2006 to SEK 459 million... (More)
- The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. This study was performed to estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including costs of long-term sick leave and disability pension, was estimated as the difference between psoriasis patients and matched controls from the general population. Total direct cost increased from SEK 348 million (similar to(sic)39) in 2006 to SEK 459 million (similar to(sic)51) in 2009, whereas the total productivity loss decreased from SEK 1,646 (similar to(sic)183) to 1,618 million (similar to(sic)180) between 2006 and 2009. Although direct costs, especially for biologic agents, have increased for patients with psoriasis over time, this study indicates that costs related to productivity loss are still more substantial. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5194581
- author
- Norlin, Jenny M.
; Steen Carlsson, Katarina
LU
; Persson, Ulf
LU
and Schmitt-Egenolf, Marcus
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- psoriasis, cost of illness, productivity loss, biologics
- in
- Acta Dermato-Venereologica
- volume
- 95
- issue
- 2
- pages
- 156 - 161
- publisher
- Medical Journals Limited
- external identifiers
-
- wos:000349270900007
- scopus:84928235405
- pmid:24819980
- ISSN
- 1651-2057
- DOI
- 10.2340/00015555-1895
- language
- English
- LU publication?
- yes
- id
- c63afe3a-5ffa-462c-8b3b-9b12fff194c6 (old id 5194581)
- date added to LUP
- 2016-04-04 09:11:02
- date last changed
- 2023-09-05 20:21:25
@article{c63afe3a-5ffa-462c-8b3b-9b12fff194c6,
abstract = {{The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. This study was performed to estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including costs of long-term sick leave and disability pension, was estimated as the difference between psoriasis patients and matched controls from the general population. Total direct cost increased from SEK 348 million (similar to(sic)39) in 2006 to SEK 459 million (similar to(sic)51) in 2009, whereas the total productivity loss decreased from SEK 1,646 (similar to(sic)183) to 1,618 million (similar to(sic)180) between 2006 and 2009. Although direct costs, especially for biologic agents, have increased for patients with psoriasis over time, this study indicates that costs related to productivity loss are still more substantial.}},
author = {{Norlin, Jenny M. and Steen Carlsson, Katarina and Persson, Ulf and Schmitt-Egenolf, Marcus}},
issn = {{1651-2057}},
keywords = {{psoriasis; cost of illness; productivity loss; biologics}},
language = {{eng}},
number = {{2}},
pages = {{156--161}},
publisher = {{Medical Journals Limited}},
series = {{Acta Dermato-Venereologica}},
title = {{Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden}},
url = {{https://lup.lub.lu.se/search/files/5254479/8053163.pdf}},
doi = {{10.2340/00015555-1895}},
volume = {{95}},
year = {{2015}},
}